"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology - Dallas Presbyterian Hospital conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 22 clinical trials were completed, i.e. on average, 64.7% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 10 clinical trials were completed. i.e. 55.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology - Dallas Presbyterian Hospital" #1 sponsor was "Novartis Pharmaceuticals" with 9 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "Seagen Inc." with 3 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology - Dallas Presbyterian Hospital" #1 collaborator was "Bristol-Myers Squibb" with 4 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "ARMO BioSciences" with 2 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator and "Hoffmann-La Roche" with 2 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology - Dallas Presbyterian Hospital" are "Breast Cancer" (14 trials), "Metastatic Breast Cancer" (6 trials), "Breast Neoplasms" (4 trials), "Fallopian Tube Cancer" (3 trials) and "Neoplasm Metastasis" (3 trials). Many other conditions were trialed in "Texas Oncology - Dallas Presbyterian Hospital" in a lesser frequency.

Most popular intervention types in "Texas Oncology - Dallas Presbyterian Hospital" are "Drug" (50 trials), "Biological" (7 trials), "Other" (2 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Fulvestrant" (6 trials), "Abemaciclib" (3 trials), "Docetaxel" (3 trials) and "Letrozole" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology - Dallas Presbyterian Hospital" are 43 trials for "All" genders, 18 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology - Dallas Presbyterian Hospital". undefined are not yet recruiting, 12 are recruiting, 17 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Texas Oncology - Dallas Presbyterian Hospital, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology - Dallas Presbyterian Hospital, 0 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".